TMX Group | Jotup

Canadian North Resources Inc. Announces Normal Course Issuer Bid Share

Retrieved on:

Friday, April 5, 2024

Indian stock exchange, NCBI, TSX Venture Exchange, TMX Group, Acquisition, CNRI, National instrument, News

TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- Canadian North Resources Inc. (“CNRI” or “the Company,” TSXV: CNRI; OTCQX: CNRSF; FSE: EO0 (E-O-zero)) announces that it has filed with the TSX Venture Exchange a Notice of Intention to Make a Normal Course Issuer Bid (“NCIB”) which is proposed to commence on April 10, 2024 and terminate on April 9, 2025 or the earlier of the date all shares which are subject to the Normal Course Issuer Bid are purchased.

Key Points:

TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- Canadian North Resources Inc. (“CNRI” or “the Company,” TSXV: CNRI; OTCQX: CNRSF; FSE: EO0 (E-O-zero)) announces that it has filed with the TSX Venture Exchange a Notice of Intention to Make a Normal Course Issuer Bid (“NCIB”) which is proposed to commence on April 10, 2024 and terminate on April 9, 2025 or the earlier of the date all shares which are subject to the Normal Course Issuer Bid are purchased.
In the opinion of the Board of Directors of the Company, the market price of the Common Shares does not accurately reflect the value of those shares.
As a result, the Company intends to repurchase CNRI’s Common Shares that may become available for purchase at prices, which make them an appropriate use of funds of the Company.
The technical contents of this News Release have been reviewed and approved by Dr. Trevor Boyd, P.Geo., a Qualified Person as defined by Canadian National Instrument 43-101 standards.

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on:

Wednesday, April 3, 2024

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points:

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

POET to Present at the AI & Technology Hybrid Investor Conference Presented by Water Tower Research on April 10

Retrieved on:

Wednesday, April 3, 2024

Optics, Conference, Communication, TMX Group, AI, Die (integrated circuit), POET, Programmable interrupt controller, PTK

TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. (POET) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for data center, telecommunication and AI markets today announced that Dr. Suresh Venkatesan, Chairman & CEO, will present live at the AI & Technology Hybrid Investor Conference presented by Water Tower Research and hosted by VirtualInvestorConferences.com, on April 10, 2024.

Key Points:

TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. (POET) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for data center, telecommunication and AI markets today announced that Dr. Suresh Venkatesan, Chairman & CEO, will present live at the AI & Technology Hybrid Investor Conference presented by Water Tower Research and hosted by VirtualInvestorConferences.com, on April 10, 2024.
This will be a live, interactive online event where investors are invited to ask the Company questions in real time.
POET announced the immediate availability of Wavelight™, the Company’s debut entry into the 800G Optical Module market targeted at AI cluster and data center operators.
Also at OFC, POET demonstrated Starlight™, an 8-channel packaged light source powering chip-to-chip communication in AI clusters and next generation cloud data center networks.

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on:

Tuesday, April 2, 2024

Hospital, TMX Group, Teaching hospital, Phase, OTCQB, Liver

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points:

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
The three new hospitals joining the Phase II study are Istanbul University-Cerrahpaşa, Sütçü İmam University Hospital in the city of Kahramanmaraş, and the Gazi University Hospital in Ankara, the capital of Turkey.
The trial now has a total of seven clinical sites across Turkey and Canada.

Robex Announces Share Consolidation

Retrieved on:

Thursday, March 28, 2024

Letter, CUSIP, TMX Group, Consolidation, NOT, Effective date, Security (finance)

QUEBEC CITY, March 28, 2024 (GLOBE NEWSWIRE) -- Robex Resources Inc. ("Robex" or the "Company") (TSXV: RBX) announces today that its Board of Directors has approved the implementation of the consolidation of the issued and outstanding common shares of the Company approved by its shareholders on June 29, 2023, on the basis of one (1) post-consolidation common share for ten (10) pre-consolidation common shares (the "Consolidation"), which will take effect on April 1st, 2024 (the "Effective Date").

Key Points:

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
QUEBEC CITY, March 28, 2024 (GLOBE NEWSWIRE) -- Robex Resources Inc. ("Robex" or the "Company") (TSXV: RBX) announces today that its Board of Directors has approved the implementation of the consolidation of the issued and outstanding common shares of the Company approved by its shareholders on June 29, 2023, on the basis of one (1) post-consolidation common share for ten (10) pre-consolidation common shares (the "Consolidation"), which will take effect on April 1st, 2024 (the "Effective Date").
After the Consolidation, the shares will have a new CUSIP number and a new ISIN number.
The Consolidation will reduce the number of issued and outstanding common shares of the Company from approximately 844,054,403 common shares to 84,405,449 common shares upon completion of the Consolidation.
No fractional common shares will be issued in connection with the Consolidation and all fractional common shares that would otherwise have been issued will be rounded to the nearest whole common share.

POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks

Retrieved on:

Wednesday, March 27, 2024

IO, DSP, SAN, LPO, TMX Group, AI, Die (integrated circuit), POET, Programmable interrupt controller, Product management, PTK, Video game

POET and MultiLane will focus on jointly developing pluggable transceivers that will reduce cost and improve power efficiency over existing solutions, and address the increasing need for more scalable hardware components for AI and cloud data center markets.

Key Points:

POET and MultiLane will focus on jointly developing pluggable transceivers that will reduce cost and improve power efficiency over existing solutions, and address the increasing need for more scalable hardware components for AI and cloud data center markets.
“Our intent with this collaboration is to design cost-optimized 800G modules that offer superior performance with both the DSP integrated version as well as Linear Pluggable Optics (LPO) variants.
We also want to kick start our designs for 1.6T and 3.2T pluggable transceivers for the most advanced data center and AI network operators,” said Raju Kankipati, POET’s SVP of Product Management.
“We have to plan and develop ahead of market demand and be ready when customers are ready to test these higher speeds.

Abcourt Closes a First Tranche of the Private Placement of Units Previously Announced, for an Amount of $1,436,234

Retrieved on:

Tuesday, March 26, 2024

Cloud, Giant, Indian stock exchange, Control, TSX Venture Exchange, Private, Exercise, Offering, Minority, ABI, Sale, TMX Group, WIRE, News, NOT, Multilateral, NEWS, Security (finance)

ROUYN-NORANDA, Quebec, March 26, 2024 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) announces that it has completed a first closing of the non-brokered private placement announced on March 12, 2024, for gross proceeds of $1,436,234, representing 28,724,688 units of the Corporation (the “Units”), at a price of $0.05 per Unit (the "Offering"). Each Unit consists of one common share of the Corporation (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at a price of $0.06 for a period of 36 months following the closing date of the Offering.

Key Points:

Each Unit consists of one common share of the Corporation (a “Common Share”) and one common share purchase warrant (a “Warrant”).
Each Warrant entitles the holder thereof to purchase one Common Share at a price of $0.06 for a period of 36 months following the closing date of the Offering.
Abcourt paid finder’s fees in an amount of $500 and issued 10,000 finder warrants to Red Cloud Securities Inc., who assisted Abcourt by introducing a subscriber to the Corporation in connection with the Offering.
As a result, François Mestrallet will become a Control Person of the Corporation.

POET Enters Optical Module Market with 800G Transceiver for Artificial Intelligence Networks

Retrieved on:

Tuesday, March 26, 2024

OSFP, Optics, GM, Intelligence, SAN, Meta, TMX Group, AI, Die (integrated circuit), POET, Senior, AWS, Wavelight, SPX, Programmable interrupt controller, Product management, CWDM, PTK, Silicon

TORONTO and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center, telecommunication and AI markets, today announced its first entry into the optical module market for artificial intelligence and cloud data center markets with an 800G pluggable transceiver.

Key Points:

TORONTO and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center, telecommunication and AI markets, today announced its first entry into the optical module market for artificial intelligence and cloud data center markets with an 800G pluggable transceiver.
The Wavelight™ is an 800G 2xFR4 OSFP module that incorporates the Company’s POET Optical Interposer™ technology and related optical engine products.
Wavelight is the Company’s first POET-branded module and its initial entry into the pluggable optical module market, representing a key milestone in its commercialization roadmap.
POET debuts in the module market at the leading edge of module designs at a speed and performance that is highly sought after by AI network operators such as Google, Meta, Nvidia and AWS.

Women in Governance Opens the Market

Retrieved on:

Friday, April 5, 2024

Organization, Wig, WTW, TMX Group, Parity, Accenture, Multimedia

WiG's Parity Certification™ enables organizations to close the gender gap at every level.

Key Points:

WiG's Parity Certification™ enables organizations to close the gender gap at every level.
With the support of its partners Accenture, Mercer and WTW, WiG evaluates and guides organizations on their journey towards parity, taking into account intersectionality and the multiple facets of diversity, equity, and inclusion.
At its launch in 2017, 17 prestigious organizations had enrolled in the Parity Certification™.
To date, WiG has certified 123 organizations, including the most prestigious ones in the FP500.

AM Resources Acquires Significant Land Package in the Austrian Pegmatite Belt

Retrieved on:

Thursday, March 21, 2024

Element, Mining, Geology, Staurolite, Warrant, TMX Group, Acquisition, Leucogranite, Mineral, AMR, Plant, TSX, European, Wolfsberg, Government, Gneiss, Lithium

Newly acquired 1,500 km2 land package gives AM Resources control over a large area of the Austrian Pegmatite Belt.

Key Points:

Newly acquired 1,500 km2 land package gives AM Resources control over a large area of the Austrian Pegmatite Belt.
New land package includes the Frederick Property, where 112 pegmatites were identified over an area of 52.25 km2.
The newly acquired land is located in the Austrian Pegmatite Belt within the Austroalpine Nappes, known for its geological diversity and rich mineral endowment.
This property demonstrates the exceptional potential of the Austrian Pegmatite Belt.